ArticleIDCases2021
Corticosteroids in Covid-19 pandemic have the potential to unearth hidden burden of strongyloidiasis.
Article in IDCases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Strongyloides Hyperinfection Syndrome Following Immunosuppressant Therapy for COVID-19: A Case Report With Literature Review.Clinical case reports · 2024Article
- Prevalence of asymptomatic strongyloidiasis co-infection in COVID-19 patients residing in endemic areas.European journal of medical research · 2023Article
- Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review.The American journal of tropical medicine and hygiene · 2023Article
- Co-infection of COVID-19 and parasitic diseases: A systematic review.Parasite epidemiology and control · 2023Review
- Coinfection withTropical medicine and infectious disease · 2023Review
- From past to present: opportunities and trends in the molecular detection and diagnosis of Strongyloides stercoralis.Parasites & vectors · 2023Review
- Strongyloides and COVID-19: Challenges and Opportunities for Future Research.Tropical medicine and infectious disease · 2023Review
- Prevalence and risk factors of Strongyloides stercoralis in haemodialysis in Cochabamba, Bolivia: a cross-sectional study.BMC nephrology · 2023Article
- Review
- Evaluation of Strongyloides Awareness and Knowledge among Canadian Physicians Caring for Patients At Risk for Severe Strongyloidiasis: A National Cross-sectional Survey.The American journal of tropical medicine and hygiene · 2022Article
- Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids.Emerging infectious diseases · 2022Article
- Using newly optimized genetic tools to probe Strongyloides sensory behaviors.Molecular and biochemical parasitology · 2022Review
- COVID-19 and strongyloidiasis: what to expect from this coinfection?Clinics (Sao Paulo, Brazil) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 pandemic has posed formidable public health and clinical challenges to the entire humanity. A significant proportion of the COVID-19 patients have been provided immunosuppressive agents, particularly corticosteroids, as a part of management of moderate to severe COVID-19 disease. This has the drawback of development of strongyloides hyperinfection to disseminated infection in latent strongyloides infection patients. We are reporting the case of strongyloidiasis hyperinfection in a COVID-19 patient from a developing country, who initially received corticosteroid therapy for management of COVID-19, but later presented to hospital with non-specific, strongyloides related symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.